EyePoint (EYPT) reported third-quarter 2026 revenue of $0.8 million and a net loss of $95.6 million, or $1.07 per basic and diluted share. The company had $118 million in cash, cash equivalents and marketable securities as of September 30.
The company said it is prioritizing its DURAVYU diabetic macular edema program following results from its wet age-related macular degeneration studies. Its Phase 3 COMO and CAPRI DME trials are fully enrolled, with topline data expected early in the fourth quarter of 2027.
- Third-quarter revenue was $0.8 million, compared with $1.0 million a year earlier.
- Operating expenses totaled $97.6 million, versus $63.0 million in the prior-year quarter.
- EyePoint expects a roughly 53% workforce reduction and operational adjustments to generate about $30 million in annualized savings.
- The company expects its cash resources, including $10 million raised after quarter-end, to fund operations into late third quarter of 2027.
- Phase 2 VERONA results showed a 7.1-letter improvement in best-corrected visual acuity at Week 24 for DURAVYU 2.7 mg.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- KAREN L. ZADEREJ purchased 10,600 shares for an estimated $52,258
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EYPT Hedge Fund Activity
We have seen 96 institutional investors add shares of $EYPT stock to their portfolio, and 88 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP added 1,775,000 shares (+62.8%) to their portfolio in Q2 2026, for an estimated $25,382,500
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,527,792 shares (+46.3%) to their portfolio in Q2 2026, for an estimated $21,847,425
- CORMORANT ASSET MANAGEMENT, LP removed 1,265,000 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $18,089,500
- MORGAN STANLEY removed 759,379 shares (-69.3%) from their portfolio in Q2 2026, for an estimated $10,859,119
- TWO SIGMA INVESTMENTS, LP added 750,828 shares (+174.5%) to their portfolio in Q2 2026, for an estimated $10,736,840
- PATIENT SQUARE CAPITAL LP removed 720,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $2,354,400
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 647,613 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,260,865
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
